BioCentury
ARTICLE | Distillery Therapeutics

Therapeutics: Interleukin-2 receptor α chain (CD25)

September 1, 2016 7:00 AM UTC

Mouse studies suggest a conjugate of an anti-CD25 mAb and a near-infrared (NIR) light-sensitive dye could help treat cancer. In cultures of a CD25-expressing mouse T cell line exposed to NIR, a conjugate composed of Fab fragments from an anti-CD25 mAb linked to the silica-phthalocyanine dye IRDye 700DX bound to CD25 and increased T cell death compared with a conjugate consisting of the dye linked to a control antibody. In mouse models of lung cancer and colon cancer exposed to NIR light at the tumor site, the conjugate decreased tumor growth and increased survival. In a bilateral mouse model of lung cancer exposed to NIR light on only one side, the anti-CD25-dye conjugate decreased tumor growth at both tumor sites and increased survival. Next steps include selecting a conjugate suitable for clinical trials.

ADC Therapeutics S.a.r.l. and Genmab A/S have HuMax-TAC-ADC, an antibody-drug conjugate (ADC) composed of HuMax-TAC, a human mAb targeting CD25, and a pyrrolobenzodiazepine (PBD) dimer toxin, in Phase I testing for acute myelogenous leukemia (AML), Hodgkin's disease and Non-Hodgkin's lymphoma (NHL). ...